Cost-effectiveness analysis of XELOX versus XELOX plus bevacizumab for metastatic colorectal cancer in a public hospital school

Overview of attention for article published in BMC Cancer, October 2017

Altmetric Badge

About this Attention Score

Above-average Attention Score compared to outputs of the same age (54th percentile)
Good Attention Score compared to outputs of the same age and source (66th percentile)

Mentioned by

policy: 1 policy source

Citations

dimensions_citation: 7 Dimensions

Readers on

mendeley: 33 Mendeley

Summary Policy documents Dimensions citations

So far, Altmetric has seen 1 policy document that references this research output.

Encorafenib plus cetuximab for previously treated BRAF V600E mutation-positive metastatic colorectal cancer : Appraisal consultation committee papers

Cited by National Institute for Health and Care Excellence on 21 Aug 2020

The National Institute for Health and Care Excellence (NICE) in the UK provides national guidance and advice to improve health and social care.

This page shows the most recent policy documents that mention this research output.

Click here to find out how to access more activity.